Enpp-1-IN-11
Enpp-1-IN-11 (compound 23) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 45 nM. Enpp-1-IN-11 exhibits low clearance in human and mouse liver microsomes, good plasma stability in human and mouse plasma. Enpp-1-IN-11 can be used for researching anticancer.
For research use only. We do not sell to patients.
- CAS No.: 2631703-04-1
- Formula: C14H14N6O3S
- Molecular Weight:346.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
Ki: 45 nM (ENPP1)[1]
In Vivo
Pharmacokinetic Parameters of Enpp-1-IN-11 in female BALB/c mice[1].
| PO (10 mg/kg) | IV (1 mg/kg) | |
| Tmax (h) | 1.2 | |
| Cmax (ng/mL) | 33.10 | 1600.20 |
| C0 (ng/mL) | 4546.51 | |
| Tmax (h) | 0.50 | 0.08 |
| AUClast (ng/mL·h) | 29.47 | 404.40 |
| AUCinf (ng/mL·h) | 31.78 | 415.55 |
| AUCextrap (%) | 7.26 | 2.68 |
| t1/2 (h) | 0.54 | 0.11 |
| MRTlast (h) | 0.66 | 0.07 |
| CL (mL/min/kg) | 40.10 | |
| VSS (L/kg) | 0.22 | |
| F (%) | <1 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2631703-04-1
-
Molecular Weight 346.36
-
Formula C14H14N6O3S
-
SMILES
O=C(NC1=CC=C(O)C(OC)=C1)CSC2=NC(N)=NC3=C2NC=N3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)